Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
Adial Pharmaceuticals (NASDAQ: ADIL) has appointed Vinay Shah as Chief Financial Officer, effective November 16, 2024. Shah brings over 25 years of experience in pharmaceutical and healthcare sectors, previously serving as CFO at Virpax Pharmaceuticals. His track record includes raising over $150 million at Aravive and contributing to Pacira Pharmaceuticals' IPO. The current CFO, Joseph Truluck, will resign on November 15, 2024, but will continue as a consultant through March 31, 2025, to ensure a smooth transition. Truluck's departure is not related to any disagreements with the company's operations or practices.
Adial Pharmaceuticals (NASDAQ: ADIL) ha nominato Vinay Shah come Direttore Finanziario, con effetto dal 16 novembre 2024. Shah porta con sé oltre 25 anni di esperienza nei settori farmaceutico e sanitario, avendo precedentemente ricoperto il ruolo di CFO presso Virpax Pharmaceuticals. Il suo curriculum include la raccolta di oltre 150 milioni di dollari presso Aravive e il contributo all'IPO di Pacira Pharmaceuticals. L'attuale CFO, Joseph Truluck, si dimetterà il 15 novembre 2024, ma continuerà come consulente fino al 31 marzo 2025, per garantire una transizione fluida. La partenza di Truluck non è correlata a disaccordi con le operazioni o le pratiche dell'azienda.
Adial Pharmaceuticals (NASDAQ: ADIL) ha nombrado a Vinay Shah como Director Financiero, con efecto a partir del 16 de noviembre de 2024. Shah aporta más de 25 años de experiencia en los sectores farmacéutico y de atención médica, habiendo ocupado anteriormente el cargo de CFO en Virpax Pharmaceuticals. Su trayectoria incluye la recaudación de más de 150 millones de dólares en Aravive y su contribución a la OPI de Pacira Pharmaceuticals. El actual CFO, Joseph Truluck, dimitirá el 15 de noviembre de 2024, pero continuará como consultor hasta el 31 de marzo de 2025, para asegurar una transición fluida. La salida de Truluck no está relacionada con desacuerdos en las operaciones o prácticas de la empresa.
Adial Pharmaceuticals (NASDAQ: ADIL)는 Vinay Shah를 재무 책임자로 임명하였으며, 그 임기는 2024년 11월 16일부터 시작된다. Shah는 제약 및 헬스케어 분야에서 25년 이상의 경험을 보유하고 있으며, 이전에는 Virpax Pharmaceuticals의 CFO로 재직했다. 그의 경력에는 Aravive에서 1억 5천만 달러 이상을 모금한 것과 Pacira Pharmaceuticals의 IPO에 기여한 것이 포함된다. 현재 CFO인 Joseph Truluck은 2024년 11월 15일에 사임할 예정이지만, 2025년 3월 31일까지 컨설턴트로 계속 활동하여 원활한 전환을 보장할 것이다. Truluck의 사임은 회사의 운영 또는 관행과의 불일치와 관련이 없다.
Adial Pharmaceuticals (NASDAQ: ADIL) a nommé Vinay Shah au poste de Directeur Financier, à compter du 16 novembre 2024. Shah apporte plus de 25 ans d'expérience dans les secteurs pharmaceutique et de la santé, ayant précédemment exercé la fonction de CFO chez Virpax Pharmaceuticals. Son parcours comprend la levée de plus de 150 millions de dollars chez Aravive et sa contribution à l'introduction en bourse de Pacira Pharmaceuticals. L'actuel CFO, Joseph Truluck, démissionnera le 15 novembre 2024, mais continuera en tant que consultant jusqu'au 31 mars 2025, afin d'assurer une transition en douceur. Le départ de Truluck n'est pas lié à des désaccords avec les opérations ou pratiques de l'entreprise.
Adial Pharmaceuticals (NASDAQ: ADIL) hat Vinay Shah zum Chief Financial Officer ernannt, der ab dem 16. November 2024 im Amt sein wird. Shah bringt über 25 Jahre Erfahrung im pharmazeutischen und Gesundheitssektor mit und war zuvor CFO bei Virpax Pharmaceuticals. Zu seinem Leistungsausweis gehört die Beschaffung von über 150 Millionen US-Dollar bei Aravive sowie sein Beitrag zum Börsengang von Pacira Pharmaceuticals. Der derzeitige CFO, Joseph Truluck, wird am 15. November 2024 zurücktreten, aber bis zum 31. März 2025 weiterhin als Berater tätig sein, um einen reibungslosen Übergang sicherzustellen. Trulucks Ausscheiden steht nicht im Zusammenhang mit Meinungsverschiedenheiten über die Betriebsweise oder Praktiken des Unternehmens.
- Appointment of experienced CFO with over 25 years in pharmaceutical sector
- New CFO's proven track record in fundraising ($150M+ at previous company)
- Smooth transition period arranged with departing CFO through consulting agreement
- Departure of current CFO could potentially disrupt ongoing financial operations
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company’s Chief Financial Officer, effective November 16, 2024.
Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), where he focused on implementing fundraising and strategic initiatives, managed all financial operations, and co-managed investor relations. Previously, at Aravive, Inc., Mr. Shah helped raise over
“We are thrilled to welcome Vinay as our new Chief Financial Officer,” said Cary Claiborne, CEO of Adial Pharmaceuticals. “Vinay brings a wealth of experience in financial strategy within the pharmaceutical industry, and his proven leadership in driving successful capital markets strategies will be invaluable as we advance AD04 and our strategic goals. Additionally, I would like to thank Joe Truluck for his numerous contributions to Adial over the years and wish him the best in his future endeavors.”
“I am excited to join the talented team at Adial Pharmaceuticals during this pivotal time,” said Vinay Shah. "Adial's commitment to developing innovative treatments that address critical unmet needs aligns with my own passion for advancing impactful healthcare solutions. I look forward to contributing to Adial’s growth and supporting their strategic objectives as we work to deliver value for patients, partners, and shareholders.”
On November 1, 2024, Joseph Truluck notified the CEO of the Company of his decision to resign from his position as the Company’s Chief Financial Officer to pursue other opportunities. Mr. Truluck will remain CFO of the Company until November 15, 2024 and has entered into a consulting agreement with Adial, through March 31, 2025, in order to aid in an orderly transition. Mr. Truluck’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices, including any matters concerning the Company’s controls or any financial or accounting-related matters or disclosures.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
If you are interested in exploring partnership opportunities with Adial, we invite you to reach out to us (BD@adialpharma.com) to discuss how our joint efforts can bring about positive change in the millions of patients who are struggling with addiction.
Forward-Looking Statements
This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the expected contribution of Mr. Shah, advancing AD04 and our strategic goals, delivering value for our patients, partners, and shareholders and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, Mr. Shah’s ability to contribute to our growth and support our strategic objectives, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com
FAQ
When will Vinay Shah start as CFO of Adial Pharmaceuticals (ADIL)?
What is Vinay Shah's previous experience before joining Adial Pharmaceuticals (ADIL)?